慢性腎臓病患者における腎障害軽減効果を薬剤NNC0519-0130の異なる投与量で比較する研究

基本情報

NCT ID: NCT06717698
ステータス: 募集中
試験のフェーズ: 第2相
試験タイプ: 介入
目標被験者数: 465
治験依頼者名: Novo Nordisk A/S

概要

The study evaluates the safety of different doses of a new medicine called NNC0519 0130. It also looks into how the medicine may improve kidney function in participants with chronic kidney disease with or without type 2 diabetes, living with overweight or obesity. The participants will either get NNC0519-0130 (a new medicine), semaglutide (a medicine that doctors can already prescribe), or placebo (a "dummy" substance). Which treatment the participant will get is decided by chance. The study will last for up to 43 weeks.

対象疾患

Chronic Kidney Disease

介入

NNC0519-0130(DRUG)

Placebo(DRUG)

Semaglutide(DRUG)

依頼者（Sponsor）

ノボノルディスクファーマ株式会社(INDUSTRY)

実施施設 (14)

藤沢市民病院

Kanagawa, Japan(RECRUITING)

Koshigaya Municipal Hospital_Internal medicine

Saitama, Japan(ACTIVE_NOT_RECRUITING)

新田東クリニック

Sendai-shi, Miyagi, Japan(RECRUITING)

近江八幡市立総合医療センター

Siga, Japan(ACTIVE_NOT_RECRUITING)

Hanyu General Hospital_Internal Medicine

Saitama, Japan(COMPLETED)

Seino Internal Medicine Clinic_Internal medicine

Koriyama-shi, Fukushima, Fukushima, Japan, Japan(ACTIVE_NOT_RECRUITING)

医療法人社団光慈会　加藤内科クリニック

Tokyo, Japan(RECRUITING)

糖尿病・内分泌内科クリニックＴＯＳＡＫＩ

Aichi, Japan(ACTIVE_NOT_RECRUITING)

Naka Kinen Clinic_Internal medicine

Ibaraki, Japan(RECRUITING)

医療法人社団福和会　福和クリニック

Tokyo, Japan(ACTIVE_NOT_RECRUITING)

さかい内科クリニック

Kita-ku, Tokyo, Japan(ACTIVE_NOT_RECRUITING)

Naka Kinen Clinic_Internal medicine

Ibaraki, Japan(ACTIVE_NOT_RECRUITING)

かとう泌尿器科・内科・外科クリニック

Tokyo, Japan(ACTIVE_NOT_RECRUITING)

Tokyo-Eki Center-building Clinic_Internal Medicine

Tokyo, Japan(ACTIVE_NOT_RECRUITING)